Published in Chemotherapy on April 04, 1995
Immunomodulating effect of fosfomycin on gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother (1997) 1.00
Fosfomycin. Clin Microbiol Rev (2016) 0.89
Testing the mutant selection window hypothesis in vitro and in vivo with Staphylococcus aureus exposed to fosfomycin. Eur J Clin Microbiol Infect Dis (2014) 0.79
Fosfomycin: Uses and potentialities in veterinary medicine. Open Vet J (2014) 0.77
Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study. J Antibiot (Tokyo) (2016) 0.75
Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. N Engl J Med (1991) 3.14
Serum ferritin in patients with iron overload and with acute and chronic liver diseases. Gastroenterology (1975) 2.58
Inflammation and liver cancer: new molecular links . Ann N Y Acad Sci (2009) 2.29
Insulin-like growth factor-I reverts testicular atrophy in rats with advanced cirrhosis. Hepatology (2000) 2.24
Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatol (2000) 2.22
Site-specific differences in the fatty acid composition of abdominal adipose tissue in an obese population from a Mediterranean area: relation with dietary fatty acids, plasma lipid profile, serum insulin, and central obesity. Am J Clin Nutr (2001) 2.08
New therapies for hepatocellular carcinoma. Oncogene (2006) 2.05
Partial splenic embolization for the treatment of hypersplenism in cirrhosis. Hepatology (1993) 1.95
Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. Gut (2000) 1.82
Transduction of hepatocellular carcinoma (HCC) using recombinant adeno-associated virus (rAAV): in vitro and in vivo effects of genotoxic agents. J Hepatol (2000) 1.73
Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. Hepatology (1998) 1.67
Serum ferritin assay and iron status in chronic renal failure and haemodialysis. Br Med J (1975) 1.61
The problem of aging human remains and living individuals: a review. Forensic Sci Int (2009) 1.59
Enhanced magnification endoscopy: a new technique to identify specialized intestinal metaplasia in Barrett's esophagus. Gastrointest Endosc (2001) 1.59
Adenovirus-mediated CD40 ligand gene therapy in a rat model of orthotopic hepatocellular carcinoma. Hepatology (2001) 1.56
Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology (1996) 1.56
Fecal antibody responses to symptomatic and asymptomatic rotavirus infections. J Infect Dis (1993) 1.46
Liver transplantation in cirrhotic patients with diabetes mellitus: midterm results, survival, and adverse events. Liver Transpl (2001) 1.44
Magnesium binding to the bacterial chemotaxis protein CheY results in large conformational changes involving its functional surface. J Mol Biol (1994) 1.44
Rituximab in CD20 positive multiple myeloma. Leukemia (2007) 1.40
Blood ammonia levels as early indicator of allograft viability in human orthotopic liver transplantation. Am J Gastroenterol (1994) 1.38
Liver transplantation in cirrhotic patients over 60 years of age. Rev Esp Enferm Dig (1998) 1.38
[Rapid and slow progression of the infection by the type 1 human immunodeficiency virus in a population of seropositive subjects in Madrid]. Med Clin (Barc) (1996) 1.38
Immunohistochemical detection of chloride/bicarbonate anion exchangers in human liver. Hepatology (1994) 1.32
Effects of specific antibodies against Streptococcus pneumoniae on pharmacodynamic parameters of beta-lactams in a mouse sepsis model. Antimicrob Agents Chemother (2002) 1.32
CraA, a major facilitator superfamily efflux pump associated with chloramphenicol resistance in Acinetobacter baumannii. Antimicrob Agents Chemother (2009) 1.27
Hepatoprotective effects of insulin-like growth factor I in rats with carbon tetrachloride-induced cirrhosis. Gastroenterology (1997) 1.25
Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon. J Hepatol (1994) 1.25
Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl (2001) 1.25
Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology (1989) 1.20
Leukocyte-cell adhesion: a molecular process fundamental in leukocyte physiology. Immunol Rev (1990) 1.18
Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin in Spain: clonal diversity and appearance of ciprofloxacin-resistant epidemic clones. Antimicrob Agents Chemother (2001) 1.18
Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J Immunol (2000) 1.17
Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection. J Virol (2010) 1.15
Implication of human N-alpha-acetyltransferase 5 in cellular proliferation and carcinogenesis. Oncogene (2008) 1.15
Transmission of hepatitis C virus infection to tree shrews. Virology (1998) 1.14
Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Leukemia (2006) 1.13
Evaluation of single and double centrifugation tube methods for concentrating equine platelets. Res Vet Sci (2006) 1.13
Induction of cytotoxic T lymphocytes in mice against the principal neutralizing domain of HIV-1 by immunization with an engineered T-cytotoxic-T-helper synthetic peptide construct. Cell Immunol (1992) 1.12
Hepatitis B and C viral infections in patients with hepatocellular carcinoma. Hepatology (1992) 1.10
The role of the yeast plasma membrane SPS nutrient sensor in the metabolic response to extracellular amino acids. Mol Microbiol (2001) 1.10
Amphiregulin: a new growth factor in hepatocarcinogenesis. Cancer Lett (2007) 1.08
Osteopenia in rats with liver cirrhosis: beneficial effects of IGF-I treatment. J Hepatol (1998) 1.07
Identification of a novel adhesion molecule in human leukocytes by monoclonal antibody LB-2. FEBS Lett (1987) 1.05
Hepatic and extrahepatic HCV RNA strands in chronic hepatitis C: different patterns of response to interferon treatment. Hepatology (1993) 1.05
Liver cytoprotection by prostaglandins. Pharmacol Ther (1993) 1.05
Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology (2001) 1.04
7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma. Am J Pathol (1999) 1.03
Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters. Hepatology (1995) 1.03
Insulin-like growth factor I improves intestinal barrier function in cirrhotic rats. Gut (2006) 1.02
Thermodynamic analysis of the chemotactic protein from Escherichia coli, CheY. Biochemistry (1993) 1.02
A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma. Cancer Gene Ther (2010) 1.02
DIO-1 is a gene involved in onset of apoptosis in vitro, whose misexpression disrupts limb development. Proc Natl Acad Sci U S A (1999) 1.02
The expression of human intercellular adhesion molecule-2 is refractory to inflammatory cytokines. Eur J Immunol (1991) 1.02
Nitrogen movement between host and tumor in mice inoculated with Ehrlich ascitic tumor cells. Cancer Res (1984) 1.02
The response of the hepatocyte to ischemia. Liver Int (2007) 1.01
Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression. Am J Pathol (1998) 1.01
Activity of fluconazole: postantifungal effect, effects of low concentrations and of pretreatment on the susceptibility of Candida albicans to leucocytes. J Antimicrob Chemother (1994) 1.01
Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. Eur J Immunol (2001) 1.01
Localization of the repetitive telomeric sequence (TTAGGG)n in four salmonid species. Genome (1996) 1.00
Identification of heat shock protein 90 and other proteins as tumour antigens by serological screening of an ovarian carcinoma expression library. Br J Cancer (2002) 1.00
Polarity of immunogens: implications for vaccine design. Eur J Immunol (1990) 1.00
Treatment of colorectal and hepatocellular carcinomas by adenoviral mediated gene transfer of endostatin and angiostatin-like molecule in mice. Gut (2004) 1.00
In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives. J Antimicrob Chemother (2007) 1.00
Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology (1997) 1.00
Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology (1997) 0.99
Low doses of insulin-like growth factor-I improve nitrogen retention and food efficiency in rats with early cirrhosis. J Hepatol (1997) 0.99
Ex vivo antibacterial properties of rufloxacin compared with those of norfloxacin in a study with healthy volunteers. Antimicrob Agents Chemother (1996) 0.99
N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis C: a pilot study. J Interferon Res (1993) 0.99
Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12. Gene Ther (2001) 0.98
Nuclear factor-kappa B in the liver of patients with chronic hepatitis C: decreased RelA expression is associated with enhanced fibrosis progression. Hepatology (2001) 0.98
Different doses of adenoviral vector expressing IL-12 enhance or depress the immune response to a coadministered antigen: the role of nitric oxide. J Immunol (1999) 0.98
Transformed but not normal hepatocytes express UCP2. FEBS Lett (1998) 0.97
Early predictors of response to treatment in patients with chronic hepatitis C. J Hepatol (1999) 0.97
Antifibrogenic effect in vivo of low doses of insulin-like growth factor-I in cirrhotic rats. Biochim Biophys Acta (2001) 0.97
Replication of hepatitis C virus in peripheral blood mononuclear cells. Effect of alpha-interferon therapy. J Hepatol (1992) 0.97
Expression of integrins and other adhesion molecules in Epstein-Barr virus-transformed B lymphoblastoid cells and Burkitt's lymphoma cells. Int J Cancer (1992) 0.96
Effect of insulin-like growth factor I on in vivo intestinal absorption of D-galactose in cirrhotic rats. Am J Physiol (1999) 0.96
Cytogenetic recombinants from a female carrying a paracentric inversion of the short arm of chromosome number 5. Hum Genet (1983) 0.96
Interleukin-15 liver gene transfer increases the number and function of IKDCs and NK cells. Gene Ther (2008) 0.95
Antigenic and genomic diversity of human rotavirus VP4 in two consecutive epidemic seasons in Mexico. J Clin Microbiol (1998) 0.95
Plasmatic homocysteine concentration and its relationship with complications associated to diabetes mellitus. Clin Chim Acta (2002) 0.95
Impaired intestinal sugar transport in cirrhotic rats: correction by low doses of insulin-like growth factor I. Gastroenterology (1997) 0.95
In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin. Eur J Clin Microbiol Infect Dis (2000) 0.95
Permanent genetic resources added to Molecular Ecology Resources Database 1 December 2010-31 January 2011. Mol Ecol Resour (2011) 0.95
Antioxidant status and glutathione metabolism in peripheral blood mononuclear cells from patients with chronic hepatitis C. J Hepatol (1999) 0.95
Deficient display of CD3 on lymphocytes of patients with chronic fatigue syndrome. J Infect Dis (1989) 0.95
Influence of pH and concentration on the postantifungal effect and on the effects of sub-MIC concentrations of 4 antifungal agents on previously treated Candida spp. Scand J Infect Dis (2000) 0.95
Interferon alfa subtypes and levels of type I interferons in the liver and peripheral mononuclear cells in patients with chronic hepatitis C and controls. Hepatology (1999) 0.94
Liver changes in patients with hyperthyroidism. Liver (1991) 0.94
Influence of human serum on the postantifungal effect of four antifungal agents on Candida albicans. Chemotherapy (1997) 0.94
Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patients. J Hepatol (1996) 0.94
Surgical treatment of hydatid cysts of the lung. Br J Dis Chest (1974) 0.94
Quantitative analysis of the variability of nucleolar organizer regions in Salmo trutta. Genome (1993) 0.94
Splenic embolization prior to myelosuppressive treatment in hepatocarcinoma and active chronic hepatitis. Eur J Radiol (1992) 0.93
Hepatitis B virus occult infection in subjects with persistent isolated anti-HBc reactivity. J Hepatol (1993) 0.93
Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection. J Hepatol (1997) 0.93
MicroRNA losses in the frequently deleted region of 7q in SMZL. Leukemia (2007) 0.93